Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Summary

The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for neoadjuvant chemotherapy and by the update of basic translational research in the center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs, verified the effectiveness of new targeted drugs in neoadjuvant therapy.

Conditions

• Breast Neoplasm
• Breast Cancer
• Breast Tumors
• Triple-Negative Breast Cancer (TNBC)
• HER2-positive Breast Cancer
• HER2-negative Breast Cancer
• Hormone Receptor Positive Tumor
• Hormone Receptor Negative Tumor
• Early-stage Breast Cancer
• Locally Advanced Breast Cancer

Interventions

DRUG

Dalpiciclib

an oral cyclin-dependent kinases (CDK) 4/6 inhibitor

DRUG

Pyrotinib

an irreversible dual pan-erbb receptor tyrosine kinase receptor tyrosine kinase (ERBB) inhibitor

DRUG

SHR-A1811

an anti-HER2 antibody-drug conjugate (ADC)

DRUG

SHR-1316

an anti-programmed death ligand 1 (PD-L1) antibody

DRUG

Camrelizumab

an anti-programmed death-1 (PD1) antibody

DRUG

SHR-A1921

Trophoblast cell-surface antigen 2 (TROP2) ADC

DRUG

Pertuzumab

Pertuzumab

DRUG

Trastuzumab

Trastuzumab

DRUG

Goserelin

goserelin

DRUG

Letrozole

letrozole

DRUG

Nab paclitaxel

Albumin paclitaxel

DRUG

Carboplatin

Carboplatin

DRUG

Epirubicin

Epirubicin

DRUG

Cyclophosphamide

Cyclophosphamide

DRUG

Fluzoparib

an original poly adenosine diphosphate-ribose polymerase (PARP) inhibitor

DRUG

Apatinib

tyrosine kinase inhibitors

DRUG

Famitinib

tyrosine kinase inhibitors

DRUG

HB1801

Albumin docetaxel

DRUG

LEM

liposome-entrapped mitoxantrone

DRUG

TQB2102

an anti-HER2 ADC

DRUG

Benmelstobart

an anti-PDL1 antibody

DRUG

Anlotinib

an tyrosine kinase inhibitor

DRUG

TQB2868

anti-PD-1/TGF-βRII

DRUG

Ivonescimab

an anti-PD-1/VEGF bispecific antibody

DRUG

JS207

an anti-PD-1/VEGF bispecific antibody

DRUG

JSKN003

an anti-HER2 ADC

DRUG

HRS-4508

an HER2 inhibitor

DRUG

SHR-4602

an anti-HER2 ADC

DRUG

paclitaxel

paclitaxel

Sponsors & Collaborators

• Fudan University

  lead OTHER

Principal Investigators

• Zhimin Shao, Professor · Fudan University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-11-01

Primary Completion

2026-12-31

Completion

2028-09-30

Countries

• China

Study Locations